1.
Clarke C, Howard R, Rossor M, Shorvon SD, eds. Neurology: A Queen Square Textbook. Second edition. Wiley Blackwell; 2016. https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160
2.
McCarthy RA, Warrington EK. Cognitive Neuropsychology: A Clinical Introduction. Academic Press, Inc; 1990. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760
3.
Rossor M, Growdon JH. The Dementias 2. Butterworth Heinemann/Elsevier; 2007. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760
4.
Hodges JR. Cognitive Assessment for Clinicians. 3 ed. Oxford University Press; 2017. http://dx.doi.org/10.1093/med/9780198749189.001.0001
5.
Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, eds. Principles of Neural Science. Fifth edition. McGraw Hill Medical; 2013. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760
6.
Husain M. Oxford Textbook of Cognitive Neurology and Dementia. (Husain M, Schott JM, Kennard C, eds.). Oxford University Press; 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760
7.
Alzheimer’s Facts and Figures Report | Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures
8.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine. 2016;8(6):595-608. doi:10.15252/emmm.201606210
9.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. The Lancet Neurology. 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0
10.
Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. The Lancet. 2014;383(9919):828-840. doi:10.1016/S0140-6736(13)60630-3
11.
Karran E, Hardy J. Antiamyloid Therapy for Alzheimer’s Disease — Are We on the Right Road? New England Journal of Medicine. 2014;370(4):377-378. doi:10.1056/NEJMe1313943
12.
Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(4):a006213-a006213. doi:10.1101/cshperspect.a006213
13.
Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 2014;10(4):204-216. doi:10.1038/nrneurol.2014.24
14.
Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nature Reviews Disease Primers. Published online 23 April 2015. doi:10.1038/nrdp.2015.5
15.
Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. The Lancet Neurology. 2017;16(10):837-847. doi:10.1016/S1474-4422(17)30280-6
16.
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington’s disease. The Lancet Neurology. 2015;14(11):1135-1142. doi:10.1016/S1474-4422(15)00177-5
17.
Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology. 2011;10(1):31-42. doi:10.1016/S1474-4422(10)70276-3
18.
Tabrizi SJ, Reilmann R, Roos RA, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology. 2012;11(1):42-53. doi:10.1016/S1474-4422(11)70263-0
19.
Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: analysis of 36-month observational data. The Lancet Neurology. 2013;12(7):637-649. doi:10.1016/S1474-4422(13)70088-7
20.
Jones L, Houlden H, Tabrizi SJ. DNA repair in the trinucleotide repeat disorders. The Lancet Neurology. 2017;16(1):88-96. doi:10.1016/S1474-4422(16)30350-7
21.
Rossor M, Collinge J, Fox N, et al. Dementia and Cognitive Impairment. In: Clarke C, Howard R, Rossor M, Shorvon S, eds. Neurology. John Wiley & Sons, Ltd; 2016:289-336. doi:10.1002/9781118486160.ch8
22.
Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. The Lancet Neurology. 2010;9(8):793-806. doi:10.1016/S1474-4422(10)70159-9
23.
Schott JM, Fox NC, Rossor MN. Assessment and investigation of the cognitively impaired adult. In: Husain M, Schott JM, eds. Oxford Textbook of Cognitive Neurology and Dementia. Oxford University Press; 2016:221-230. doi:10.1093/med/9780199655946.003.0021
24.
Green AJE. RT-QuIC: a new test for sporadic CJD. Practical Neurology. Published online 3 October 2018. doi:10.1136/practneurol-2018-001935
25.
Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature. 2016;539(7628):217-226. doi:10.1038/nature20415
26.
Mead S, Rudge P. CJD mimics and chameleons. Practical Neurology. 2017;17(2):113-121. doi:10.1136/practneurol-2016-001571
27.
Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. The Lancet. 2015;386(10004):1683-1697. doi:10.1016/S0140-6736(15)00462-6
28.
Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica. 2011;122(2):187-204. doi:10.1007/s00401-011-0852-9
29.
Barker RA, Williams-Gray CH. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology. 2016;42(1):6-19. doi:10.1111/nan.12303
30.
Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics. 2014;23(23):6139-6146. doi:10.1093/hmg/ddu334
31.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017;89(1):88-100. doi:10.1212/WNL.0000000000004058
32.
Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in the pathogenesis of Parkinson’s disease dementia and Dementia with Lewy Bodies. F1000Research. 2017;6. doi:10.12688/f1000research.11725.1
33.
Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry. 2016;138:6-31. doi:10.1111/jnc.13654
34.
Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry. 2016;138:193-210. doi:10.1111/jnc.13656
35.
Ahmed RM, Devenney EM, Irish M, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry. 2016;87(11):1234-1241. doi:10.1136/jnnp-2014-308350
36.
Fletcher PD, Warren JD. Semantic Dementia: a specific network-opathy. Journal of Molecular Neuroscience. 2011;45(3):629-636. doi:10.1007/s12031-011-9586-3
37.
Goll JC, Crutch SJ, Loo JHY, et al. Non-verbal sound processing in the primary progressive aphasias. Brain. 2010;133(1):272-285. doi:10.1093/brain/awp235
38.
Goll JC, Ridgway GR, Crutch SJ, Theunissen FE, Warren JD. Nonverbal sound processing in semantic dementia: A functional MRI study. NeuroImage. 2012;61(1):170-180. doi:10.1016/j.neuroimage.2012.02.045
39.
Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. doi:10.1212/WNL.0b013e31821103e6
40.
Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. The Lancet Neurology. 2012;11(6):545-555. doi:10.1016/S1474-4422(12)70099-6
41.
Leyton CE, Hodges JR, McLean CA, Kril JJ, Piguet O, Ballard KJ. Is the logopenic-variant of primary progressive aphasia a unitary disorder? Cortex. 2015;67:122-133. doi:10.1016/j.cortex.2015.03.011
42.
Marshall CR, Hardy CJD, Volkmer A, et al. Primary progressive aphasia: a clinical approach. Journal of Neurology. 2018;265(6):1474-1490. doi:10.1007/s00415-018-8762-6
43.
Rohrer JD, Knight WD, Warren JE, Fox NC, Rossor MN, Warren JD. Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain. 2007;131(1):8-38. doi:10.1093/brain/awm251
44.
Rohrer JD, Ridgway GR, Crutch SJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. NeuroImage. 2010;49(1):984-993. doi:10.1016/j.neuroimage.2009.08.002
45.
Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology. 2010;75(7):603-610. doi:10.1212/WNL.0b013e3181ed9c6b
46.
Rohrer JD, Sauter D, Scott S, Rossor MN, Warren JD. Receptive prosody in nonfluent primary progressive aphasias. Cortex. 2012;48(3):308-316. doi:10.1016/j.cortex.2010.09.004
47.
Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. BMJ. 2013;347(aug12 3):f4827-f4827. doi:10.1136/bmj.f4827
48.
Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. Brain. 2017;140(5):1204-1211. doi:10.1093/brain/awx045
49.
Hollak CEM, Lachmann R, eds. Inherited Metabolic Disease in Adults: A Clinical Guide. Oxford University Press; 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760
50.
Devenney E, Vucic S, Hodges JR, Kiernan MC. Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics. 2015;15(5):509-522. doi:10.1586/14737175.2015.1034108
51.
Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2017;18(3-4):153-174. doi:10.1080/21678421.2016.1267768
52.
Iranzo A, Fernández-Arcos A, Tolosa E, et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. PLoS ONE. 2014;9(2). doi:10.1371/journal.pone.0089741
53.
Kielb SA, Ancoli-Israel S, Rebok GW, Spira AP. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. NeuroMolecular Medicine. 2012;14(3):180-193. doi:10.1007/s12017-012-8182-1
54.
Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer’s Disease? Trends in Neurosciences. 2016;39(8):552-566. doi:10.1016/j.tins.2016.05.002
55.
McCarter SJ, St. Louis EK, Boeve BF. Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports. 2016;16(9). doi:10.1007/s11910-016-0680-3
56.
Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Current Treatment Options in Neurology. 2016;18(9). doi:10.1007/s11940-016-0424-3
57.
Hardy CJD, Marshall CR, Golden HL, et al. Hearing and dementia. Journal of Neurology. 2016;263(11):2339-2354. doi:10.1007/s00415-016-8208-y
58.
Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. The Lancet. 2017;390(10113):2673-2734. doi:10.1016/S0140-6736(17)31363-6
59.
Goll JC, Crutch SJ, Warren JD. Central auditory disorders: toward a neuropsychology of auditory objects. Current Opinion in Neurology. 2010;23(6):617-627. doi:10.1097/WCO.0b013e32834027f6
60.
Husain M. Oxford Textbook of Cognitive Neurology and Dementia. (Husain M, Schott JM, Kennard C, eds.). Oxford University Press; 2016. http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760
61.
Blennow K, Hardy J, Zetterberg H. The Neuropathology and Neurobiology of Traumatic Brain Injury. Neuron. 2012;76(5):886-899. doi:10.1016/j.neuron.2012.11.021
62.
Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? Nature Reviews Neurology. 2013;9(4):211-221. doi:10.1038/nrneurol.2013.29
63.
McKee AC, Stein TD, Nowinski CJ, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(1):43-64. doi:10.1093/brain/aws307
64.
Fleminger S. Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication. Journal of Neurology, Neurosurgery & Psychiatry. 2003;74(7):857-862. doi:10.1136/jnnp.74.7.857
65.
Scott G, Ramlackhansingh AF, Edison P, et al. Amyloid pathology and axonal injury after brain trauma. Neurology. 2016;86(9):821-828. doi:10.1212/WNL.0000000000002413
66.
Hereditary and sporadic beta-amyloidoses. https://www.bioscience.org/2013/v18/af/4173/fulltext.htm
67.
Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science. 2004;117(24):5721-5729. doi:10.1242/jcs.01558
68.
Revesz T, Holton JL, Lashley T, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica. 2009;118(1):115-130. doi:10.1007/s00401-009-0501-8
69.
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3
70.
Thal DR. Neurodegeneration in Normal Brain Aging and Disease. Science of Aging Knowledge Environment. 2004;2004(23):pe26-pe26. doi:10.1126/sageke.2004.23.pe26
71.
Braak H, Braak E. Staging of alzheimer’s disease-related neurofibrillary changes. Neurobiology of Aging. 1995;16(3):271-278. doi:10.1016/0197-4580(95)00021-6
72.
Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 1991;41(4):479-479. doi:10.1212/WNL.41.4.479
73.
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathologica. 2012;123(1):1-11. doi:10.1007/s00401-011-0910-3
74.
Dobson R, Alvares D. The difficulties with vitamin B. Practical Neurology. 2016;16(4):308-311. doi:10.1136/practneurol-2015-001344
75.
Jonathan Carr. Neurosyphilis. Practical Neurology. 2003;3:328-341. https://pn.bmj.com/content/3/6/328
76.
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9
77.
Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. The Lancet. 2012;380(9843):767-777. doi:10.1016/S0140-6736(12)60069-5
78.
Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. Neurology. 2015;85(23):2063-2071. doi:10.1212/WNL.0000000000002193
79.
Arash Asher. The effect of cancer treatment on cognitive function. undefined. https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be
80.
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9
81.
Cognitive Impairment Associated with Cancer: A Brief Review. Innovations in Clinical Neuroscience. 2018;15(1-2). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/
82.
Haddow LJ, Cartledge JD, Manji H. HIV and the brain: from AIDS to old age. Clinical Medicine. 2013;13(Suppl_6):s24-s28. doi:10.7861/clinmedicine.13-6-s24
83.
Nightingale S, Michael BD, Defres S, Benjamin LA, Solomon T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. Practical Neurology. 2013;13(6):354-356. doi:10.1136/practneurol-2013-000689
84.
HIV in the United Kingdom 2016 infographic. https://www.gov.uk/government/publications/hiv-in-the-united-kingdom
85.
Itzhaki RF, Lathe R, Balin BJ, et al. Microbes and Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2016;51(4):979-984. doi:10.3233/JAD-160152
86.
Nightingale S, Winston A, Letendre S, et al. Controversies in HIV-associated neurocognitive disorders. The Lancet Neurology. 2014;13(11):1139-1151. doi:10.1016/S1474-4422(14)70137-1
87.
Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. The Journal of Infectious Diseases. 1988;158(5). https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents
88.
UK National Guidelines for HIV Testing 2008. https://www.bhiva.org/HIV-testing-guidelines
89.
Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virology Journal. 2013;10(1). doi:10.1186/1743-422X-10-172
90.
De Chiara G, Marcocci ME, Sgarbanti R, et al. Infectious Agents and Neurodegeneration. Molecular Neurobiology. 2012;46(3):614-638. doi:10.1007/s12035-012-8320-7
91.
Wendorf KA, Winter K, Zipprich J, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases. 2017;65(2):226-232. doi:10.1093/cid/cix302
92.
Ghanem KG. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics. 2010;16(5):e157-e168. doi:10.1111/j.1755-5949.2010.00183.x
93.
Somasundaram O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. Indian Journal of Psychiatry. 2009;51(3). doi:10.4103/0019-5545.55103
94.
Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke. 2006;37(9):2220-2241. doi:10.1161/01.STR.0000237236.88823.47
95.
Gorelick PB, Scuteri A, Black SE, et al. Vascular Contributions to Cognitive Impairment and Dementia. Stroke. 2011;42(9):2672-2713. doi:10.1161/STR.0b013e3182299496
96.
Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. The Lancet. 2001;357(9251):169-175. doi:10.1016/S0140-6736(00)03589-3
97.
Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. The Lancet Neurology. 2005;4(11):752-759. doi:10.1016/S1474-4422(05)70221-0
98.
O’Brien JT, Thomas A. Vascular dementia. The Lancet. 2015;386(10004):1698-1706. doi:10.1016/S0140-6736(15)00463-8
